Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Soleno Therapeutics, Inc. (SLNO)

2.81   0.22 (8.49%) 01-27 16:00
Open: 2.6 Pre. Close: 2.59
High: 2.84 Low: 2.58
Volume: 110,083 Market Cap: 23(M)

Technical analysis

as of: 2023-01-27 4:48:00 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.67     One year: 4.29
Support: Support1: 2    Support2: 1.29
Resistance: Resistance1: 3.15    Resistance2: 3.67
Pivot: 2.38
Moving Average: MA(5): 2.51     MA(20): 2.32
MA(100): 1.57     MA(250): 2.55
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 65.5     %D(3): 63.8
RSI: RSI(14): 69.5
52-week: High: 6.3  Low: 0.15
Average Vol(K): 3-Month: 2,103 (K)  10-Days: 176 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SLNO ] has closed above the upper band by 9.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 4.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.84 - 2.86 2.86 - 2.87
Low: 2.55 - 2.56 2.56 - 2.58
Close: 2.79 - 2.81 2.81 - 2.83

Company Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Headline News

Thu, 26 Jan 2023
Soleno Therapeutics (SLNO) Announces Peer-Reviewed ... - StreetInsider.com

Thu, 19 Jan 2023
Is Soleno Therapeutics Inc (SLNO) Stock About to Get Hot Thursday? - InvestorsObserver

Fri, 06 Jan 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace

Tue, 03 Jan 2023
Is Soleno Therapeutics Inc (SLNO) a Winner in the Biotechnology Industry? - InvestorsObserver

Tue, 27 Dec 2022
Healthcare Stocks Moving Tuesday: HTGM, ATNF, BDTX, SLNO, ACER, COSM, PIII, HLTH - InvestorsObserver

Tue, 20 Dec 2022
Should You Hold Soleno Therapeutics Inc (SLNO) Stock Tuesday Morning? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 8 (M)
Shares Float 5 (M)
% Held by Insiders 14.9 (%)
% Held by Institutions 38.4 (%)
Shares Short 99 (K)
Shares Short P.Month 52 (K)

Stock Financials

EPS -0.35
EPS Est Next Qtl -0.25
EPS Est This Year -1.36
EPS Est Next Year -1.05
Book Value (p.s.) 1.86
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -42.3
Return on Equity (ttm) -121
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.86
Qtrly Earnings Growth 0
Operating Cash Flow -23 (M)
Levered Free Cash Flow -13 (M)

Stock Valuations

PE Ratio -8.1
PEG Ratio -0.1
Price to Book value 1.51
Price to Sales 0
Price to Cash Flow -1.02

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-10-05
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.